Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
Lists
Only you see this
Abstract
http://www.chictr.org.cn/index.aspx (No. ChiCTR2100045107, http://www.chictr.org.cn/showproj.aspx?proj=124702).
BibTeX
@inproceedings{shu2021immunogenicity,
author = {Yajun Shu and Jianfeng He and Rongjuan Pei and Peng He and Zhuhang Huang and Shaomin Chen and Zhiqiang Ou and Jinglong Deng and Peiyu Zeng and Jian Zhou and Yuan‐Qin Min and Fēi Dèng and Hua Peng and Zheng Zhang and Bo Wang and Zhong-Hui Xu and Wuxiang Guan and Zhongyu Hu and Jikai Zhang},
title = {{Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial}},
booktitle = {Chinese},
year = {2021},
doi = {10.1097/cm9.0000000000001702},
}Loading related content...